VEGFA and non-small cell lung carcinoma: Increased VEGF levels have been identified in patients with NSCLC [8], and this had led to the inclusion of such VEGF inhibitors as bevacizumab, ramucirumab, and nintedanib in adjuvant treatment strategies for NSCLC in clinical practice [4].